

# MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Brachytherapy or Radioactive Seed Implantation for Prostate Cancer
Policy Number	6.01.16
Category	Technology Assessment
Original Effective Date	07/02/99
Committee Approval Date	07/02/01, 05/16/02, 06/19/03, 05/19/04, 05/18/05, 05/18/06, 04/19/07, 04/17/08, 04/16/09, 05/27/10, 06/16/11, 06/21/12, 06/20/13, 06/19/14, 07/16/15, 07/21/16, 08/17/17, 10/18/18, 11/21/19, 11/19/20, 11/18/21, 11/17/22, 11/16/23, 11/21/24
Current Effective Date	11/21/24
Archived Date	N/A
Archived Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> <li>• <i>Services are contract dependent; if a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</i></li> <li>• <i>If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</i></li> <li>• <i>If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</i></li> </ul>

## POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, permanent low-dose rate (LDR) brachytherapy or temporary high-dose-rate (HDR) brachytherapy for localized prostate cancer is considered **medically appropriate** in the following situations:
- A. When used alone as monotherapy for **ANY** of the following National Comprehensive Cancer Network Risk Group Levels (*Refer to Policy Guideline II*):
1. Very Low Risk;
  2. Low Risk; or
  3. Favorable Intermediate Risk;
- OR**
- B. When used as Brachytherapy Boost in conjunction with external beam radiation therapy (EBRT) for **ANY** of the following National Comprehensive Cancer Network Risk Group Levels (*Refer to Policy Guideline II*):
1. Unfavorable Intermediate Risk;
  2. High Risk; or
  3. Very High Risk
- II. Based upon our criteria and assessment of the peer reviewed literature, temporary HDR brachytherapy alone as monotherapy for high-risk prostate cancer has not been proven to be medically effective and, therefore, is considered **investigational**.

*Refer to Corporate Medical Policy #7.01.01 Focal Therapies for Prostate Cancer Treatment*

*Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services*

**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER**

Policy Number: 6.01.16

Page: 2 of 9

**POLICY GUIDELINES**

I. One (1) technique of image-guided radiation therapy (IGRT) is allowed daily when the criteria for brachytherapy are met.

II. Prostate Cancer Risk Group Definitions:

The following table was compiled utilizing the National Comprehensive Cancer Network (NCCN) V.4.2024 Prostate Cancer guidelines risk stratification and recommendations for the use of brachytherapy in the treatment of prostate cancer:

<b>Risk Group</b>	<b>Clinical/Pathologic Features</b>	<b>Brachytherapy</b>
Very low	Has all of the following: <ul style="list-style-type: none"> <li>• cT1c</li> <li>• Grade Group 1</li> <li>• PSA &lt;10ng/mL</li> <li>• Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core</li> <li>• PSA density &lt;0.15ng/mL/g</li> </ul>	N/A
Low	Has all of the following but does not qualify for very low risk: <ul style="list-style-type: none"> <li>• cT1-cT2a</li> <li>• Grade Group 1</li> <li>• PSA &lt;10 ng/mL</li> </ul>	If prognosis is ≥ 10 years
Favorable Intermediate	Has all of the following: <ul style="list-style-type: none"> <li>• No high-risk or very high-risk group features</li> <li>• Has one or more intermediate risk factors:               <ul style="list-style-type: none"> <li>○ cT2b-cT2c</li> <li>○ Grade Group 1 or 2</li> <li>○ PSA 10-20 ng/mL</li> <li>○ &lt;50% biopsy cores positive (e.g., &lt;6 of 12 cores)</li> </ul> </li> </ul>	If prognosis is 5- 10 years
Unfavorable Intermediate	Has all of the following: <ul style="list-style-type: none"> <li>• No high-risk or very high-risk group features</li> <li>• Has 2 or 3 intermediate risk factors:               <ul style="list-style-type: none"> <li>○ cT2b-cT2c</li> <li>○ Grade Group 3</li> <li>○ PSA 10-20 ng/mL</li> <li>○ ≥50% biopsy cores positive (e.g., &lt;6 of 12 cores)</li> </ul> </li> </ul>	If prognosis is 5- 10 years (Brachytherapy + EBRT+ ADT)
High	Has no very-high-risk features and has exactly one high-risk feature: <ul style="list-style-type: none"> <li>○ cT3a OR</li> <li>○ Grade Group 4 or Grade Group 5 OR</li> <li>○ PSA &gt;20 ng/mL</li> </ul>	If prognosis is > 5 years or symptomatic (Brachytherapy +EBRT + ADT)
Very high	Has at least one of the following: <ul style="list-style-type: none"> <li>○ cT3b-cT4</li> <li>○ Primary Gleason pattern 5</li> <li>○ 2 or 3 high-risk features</li> </ul>	Prognosis >5 years or symptomatic (Radiation Therapy +ADT+Abiraterone)

**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER**

**Policy Number: 6.01.16**

**Page: 3 of 9**

	o >4 cores with Grade Group 4 or 5	
--	------------------------------------	--

**DESCRIPTION**

The American Brachytherapy Society (ABS) defines brachytherapy as “Internal radiation treatment given by placing radioactive material directly into a tumor or close to it. Also called interstitial radiation therapy, intracavitary radiation therapy, intravascular radiation therapy, or seed implantation.” The radioactive material is sealed in needles, seeds, wires, or catheters which are inserted and guided by radiological imaging, usually, but not exclusively, ultrasound.

There are two major methods of prostate brachytherapy; permanent low dose rate (LDR) brachytherapy and temporary high dose rate (HDR) brachytherapy.

In LDR brachytherapy, radioactive seeds are implanted interstitially, using the transperineal route with the guidance of transrectal ultrasound, fluoroscopy and/or computed tomography. The seeds release radiation gradually at a low-dose rate, over a period of time (six to 12 months), after which they become inert. The most common seeds used in LDR brachytherapy are Iodine-125 and Palladium-103. The seeds do not have to be removed and can remain in the prostate for the rest of the patient’s life. ABS recommends that post-operative dosimetry be performed on each patient who has undergone permanent radioactive seed implantation. Without this information it is impossible to confirm the actual dose delivered or to identify any variance from the treatment plan.

In contrast, HDR brachytherapy involves placing tiny plastic catheters into the prostate gland and then delivering multiple radiation treatments, or “fractions,” through these catheters with a high energy radioisotope such as iridium-192. The radioactive source is “afterloaded,” which means it is temporarily inserted into the prostate for a calculated duration at various “dwell positions,” usually eight to 12 minutes. HDR brachytherapy can be delivered in “fractions,” which is the delivery during several sessions per day or over a course of several days. Radiation treatment planning and computerized dose calculations are needed, both to determine the prostate and tumor dose distribution and to control the radiation dose to the adjacent normal tissues such as in rectum, bladder, and urethra. HDR brachytherapy permits precise delivery of radiation at a high rate to the prostate and immediate surrounding areas. In addition to efficacy in the low- and intermediate-grade prostate cancers, it is believed to be more effective in destroying rapidly dividing cancer cells, as seen in poorly differentiated malignancies.

Brachytherapy is commonly used in conjunction with EBRT and Androgen Deprivation Therapy (ADT).

A number of devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process to deliver brachytherapy to the prostate. The Martinez Prostate Template Set and Photon Technologies HDR Prostate Template and Accessories are examples of radiation application devices. These devices are intended as accessories to commercially available HDR remote afterloader systems for prostate brachytherapy. I-Seed (Theragenics), Proxcelan Cs-131 (IsoRay Medical), and BrachySource Brachytherapy Seed Implants (C.R. Bard, Inc) are examples of permanently implanted seeds available and cleared by the FDA through the 510(k) process.

The American Society for Radiation Oncology (ASTRO) defines Image-guided radiation therapy (IGRT) as the use of dedicated devices for fraction-by-fraction imaging and guidance within the treatment room that localizes the target and normal structures at the time of treatment to assure precise and accurate placement of the radiation, and thereby pursue highly conformal dose distributions, higher dose prescriptions, and shorter fractionation schedules. IGRT can be conducted using computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and x-ray. Scans are compared to simulation reference images and allow the radiation oncologist to adjust based on the tumor position, size, shape.

Hormone therapy may be considered as a neo-adjuvant therapy to permanent seed implantation, HDR brachytherapy, or external beam radiation therapy to selectively reduce prostate size and induce tumor regression.

**RATIONALE**

Peer-reviewed literature demonstrates that LDR brachytherapy using the transperineal approach provides excellent control of the disease in low-stage and low- to moderate-grade tumors, like those with 3D conformal EBRT or radical

## Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER

Policy Number: 6.01.16

Page: 4 of 9

prostatectomy. For patients with intermediate-risk disease, 3D conformal EBRT, with or without brachytherapy, or radical prostatectomy provided comparable long-term, disease-free survival.

Morris et al. (2017) reported on the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy trial, which evaluated patients who received androgen deprivation therapy (ADT) and EBRT. The investigators compared EBRT boost with an LDR brachytherapy boost. The primary outcome (biochemical progression-free survival [PFS]) at a median follow-up of 6.5 years significantly favored the LDR brachytherapy group ( $p=.004$ ). In a subgroup analysis limited to patients with intermediate-risk prostate cancer (i.e., clinically localized disease), biochemical PFS was significantly higher in the brachytherapy boost group ( $p=.003$ ). Overall and disease-specific survival did not differ significantly between the LDR brachytherapy boost and the EBRT boost groups. In 2018, Morris published a reanalysis of the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy trial comparing biochemical failure using a prostate-specific antigen (PSA) threshold of  $>0.2$  ng/mL to the Phoenix threshold (nadir +2 ng/mL). At follow-up times  $>4$  years, patients receiving LDR permanent brachytherapy were less likely to experience biochemical failure (log rank  $p=.001$ ). The Kaplan-Meier biochemical progression free survival was superior for LDR permanent brachytherapy compared with dose-escalated EBRT.

Kee et al. (2018) published a systematic review and meta-analysis comparing brachytherapy boost and EBRT boost after EBRT for patients with prostate cancer. Three RCTs with a total of 703 participants were included. Brachytherapy boost had a significant benefit over EBRT boost for 5-year progression-free survival (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.37 to 0.66;  $p<.01$ ); there was no significant difference between the two treatments for overall survival (HR, 0.92; 95% CI, 0.64 to 1.33;  $p=.65$ ). There was also no difference in rates of  $\geq$  grade 3 late genitourinary (GU) or late gastrointestinal (GI) toxicities. No limitations for this analysis were reported.

Pasalic et al. (2021) reported on the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study, a prospective, multicenter study that evaluated 695 patients who received EBRT alone ( $n=583$ ) and EBRT plus LDR brachytherapy ( $n=112$ ) for localized prostate cancer. Adjunctive ADT was given based on a risk-based assessment and at the discretion of the clinician. The primary outcomes were patient-reported, including Expanded Prostate Cancer Index Composite domains (e.g., urinary irritative function, bowel function). After a median follow-up of 73 months, no significant differences were found between EBRT alone and EBRT plus LDR brachytherapy for 5-year and 7-year overall survival, 5-year prostate cancer-specific survival and 7-year prostate cancer-specific survival. Treatment with EBRT plus LDR brachytherapy was associated with clinically meaningful worse urinary irritative function and bowel function scores at 3 years; but the differences between treatment groups were not considered clinically meaningful at 5 years.

The Groupe Europeen de Curietherapie (GEC), the European Society for Radiotherapy and Oncology (ESTRO) and Advisory Committee for Radiation Oncology Practice (ACROP) published joint prostate brachytherapy guidelines in 2022. The group assigned a Grade B, Level 2a recommendation for the use of fractionated HDR monotherapy for low and intermediate risk prostate cancer. The authors acknowledge that the use of LDR permanent implants for monotherapy is well established, while there is less information available on the optimal dose fractionation schedules for monotherapy using HDR, but state that overall results across comparable risk groups are no different. Given the significant risk of microscopic extracapsular spread, the group recommends brachytherapy be combined with EBRT for individuals with unfavorable intermediate and high risk localized prostate cancer (Grade A, Level 1a).

Deville and colleagues published a summary of the 2022 American Urological Association (AUA)/ASTRO Guideline on Clinically Localized Prostate Cancer in 2023. The multidisciplinary panel developed recommendations based on a systematic literature review to provide guidelines pertinent to radiation oncologists. The authors address the use of radiation therapy for clinically localized prostate cancer as evolving rapidly, with new trial results, therapeutic combinations, and technological advances. Brachytherapy is only mentioned within the guidelines for its use in patients with unfavorable intermediate or high-risk prostate cancer who are electing radiation therapy. In this risk population, the group recommends that clinicians offer dose-escalated hypofractionated EBRT or combined EBRT +brachytherapy (LDR, HDR) along with a risk-appropriate course of ADT (Recommendation: Strong, Grade A/B).

A 2023 randomized clinical trial by Michalski et al. sought to determine whether the addition of EBRT to brachytherapy (COMBO) would improve the five-year freedom from progression (FFP) in intermediate- risk prostate cancer when compared to treatment with brachytherapy (BT) alone. A total of 579 men with prostate cancer stage cT1c-T2bN0M0,

## Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER

Policy Number: 6.01.16

Page: 5 of 9

Gleason Score 2-6 and PSA 10-20 or GS7, and PSA <10 were included in the trial. The COMBO arm (n=287) received EBRT to the prostate and seminal vesicles followed by BT prostate boost. The BT arm (n=292) had treatment delivered to the prostate only. The primary end point of the study was the FFP derived from PSA failure (as defined by ASTRO or Phoenix) local failure, distant failure or death. After a median follow up of 12.1 years, there were no differences between arms in FFP. Urinary and bowel late grade 2+ effects were more common within the COMBO arm, as well as more grade 3+ genitourinary late effects, while 3+ GI effects were similar between arms. The five year overall survival was 95.3% for the COMBO arm versus 93.3% for the BT arm. There were no significant differences identified in time to local progression, distant metastases, or disease specific mortality.

The NCCN V.4.2024 guidelines state that, “Interstitial implantation of prostate +/- proximal seminal vesicles with temporary (high dose-rate, HDR) or permanent (low dose-rate, LDR) radioactive sources for monotherapy or as boost when added to EBRT should be performed in practices with adequate training, experience, and quality assurance measures. Brachytherapy boost, when added to EBRT and ADT, improves biochemical control. To address historical trial data concerns for increased toxicity incidence, careful patient selection and contemporary planning associated with lesser toxicity, such as use of recognized organ at risk (OAR) dose constraints, use of high-quality ultrasound and other imaging, and prescription of dose as close as possible to the target without excessive margins should be implemented. Moreover, given trial data showing similar cancer control with lower toxicity with brachytherapy alone in unselected cohorts with intermediate-risk prostate cancer, the use of combination EBRT with brachytherapy boost is best reserved for higher risk disease and unfavorable intermediate-risk disease with several risk factors.”

Anderson et al. (2021) published a systematic review analyzing the available evidence on HDR brachytherapy as monotherapy for prostate cancer. The review included seven studies representing 2123 patients. Of the included patients, 40% were NCCN low risk, 40% were intermediate, and 20% were high risk. All of the included studies had at least five years of follow-up, a minimum of 80 patients, and biochemical recurrence free survival (BRFS) outcomes. The median follow-up was 74 months. The five-year BRFS rate was 95% (95% CI, 93% to 96%). Grade 3 or 4 genitourinary and gastrointestinal toxicity rates were low (2% and 0.3%, respectively). Given the methodology utilized within the study, patients’ treatment characteristics were reported at the study group level and therefore it is not clear whether patients with higher risk disease were included in a cohort that had received ADT. The authors are uncertain as to how this reporting may have impacted associated outcomes.

The current evidence on the use of HDR brachytherapy as a sole treatment for high risk prostate cancer patients does not demonstrate its superiority over other treatments such as EBRT. More robust clinical trials are needed and the current evidence suggests that it may be more beneficial when used in combination with EBRT or hormone therapy.

### CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.*
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*
- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).*

#### CPT Codes

Code	Description
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy
55876	Placement of interstitial device(s) for radiation therapy guidance (e.g. fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple
76873	Ultrasound, transrectal; prostate volume study for brachytherapy treatment planning (separate procedure)
76965	Ultrasonic guidance for interstitial radioelement application

**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER****Policy Number: 6.01.16****Page: 6 of 9**

<b>Code</b>	<b>Description</b>
77014	Computed tomography guidance for placement of radiation therapy fields
77021	Magnetic resonance imaging guidance for needle placement (e.g., for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation
77316	Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4 sources, or remote afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s)
77317	Brachytherapy isodose plan; intermediate (calculation[s] made from 5 to 10 sources, or remote afterloading brachytherapy, 2-12 channels), includes basic dosimetry calculation(s)
77318	Brachytherapy isodose plan; complex (calculation[s] made from over 10 sources, or remote afterloading brachytherapy, over 12 channels), includes basic dosimetry calculation(s)
77387	Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed
77761	Intracavitary radiation source application; simple
77762	Intracavitary radiation source application; intermediate
77763	Intracavitary radiation source application; complex
77778	Interstitial radiation source application; complex includes supervision, handling, loading of radiation source, when performed
77789	Surface application of low dose rate radionuclide source
77790	Supervision, handling, loading radiation source
77799	Unlisted procedure, clinical brachytherapy
<b>The following codes may be considered as E/I if used alone.</b>	
77770	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
77771	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
77772	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels

*Copyright © 2024 American Medical Association, Chicago, IL***HCPCS Codes**

<b>Code</b>	<b>Description</b>
C1716	Brachytherapy source, nonstranded, gold-198, per source
C1719	Brachytherapy source, nonstranded, non -high dose rate iridium-192, per source
C2637	Brachytherapy source, nonstranded, ytterbium-169, per source
C2638	Brachytherapy source, stranded, iodine-125, per source
C2639	Brachytherapy source, nonstranded, iodine-125, per source

**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER****Policy Number: 6.01.16****Page: 7 of 9**

<b>Code</b>	<b>Description</b>
C2640	Brachytherapy source, stranded, palladium-103, per source
C2641	Brachytherapy source, nonstranded, palladium-103, per source
C2642	Brachytherapy source, stranded, cesium-131, per source
C2643	Brachytherapy source, nonstranded, cesium-131, per source
C2645	Brachytherapy planar source, palladium-103, per square millimeter
G0458	Low dose rate (LDR) prostate brachytherapy services, composite rate
Q3001	Radioelements for brachytherapy, any type, each
<b>The following codes may be considered as E/I if used alone.</b>	
C1717	Brachytherapy source, nonstranded, high dose rate iridium-192, per source
C9725	Placement of endorectal intracavity applicator for high intensity brachytherapy

**ICD10 Codes**

<b>Code</b>	<b>Description</b>
C61	Malignant neoplasm of prostate
D07.5	Carcinoma in situ of prostate

**REFERENCES**

- \*Agarwal M, et al. Long-term outcomes analysis of low-dose-rate brachytherapy in clinical T3 high-risk prostate cancer. Brachytherapy 2018 Nov - Dec;17(6):882-887.
- \*Anderson EM, et al. High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. J Contemp Brachytherapy 2021 Aug;13(4): 365-372.
- \*Aluwini S, et al. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low-and intermediate-risk prostate cancer: a 7 year experience. Int J Oncol Biol Phys 2012 Aug 1;83(5):1480-5.
- \*Barkati M, et al. High-dose-rate brachytherapy as a monotherapy for favorable risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys 2012 Apr 1;82(5):1889-96.
- \*Benoit RM, et al. Cesium-131 prostate brachytherapy: a single institutional long-term experience. Brachytherapy May-Jun 2020;19(3):298-304.
- \*Buckstein M, et al. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up. Urology 2013;81(2):364-8.
- \*Challapalli A, et al. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol 2012 Nov;85(Spec No 1):S18-27.
- \*Chao M, et al. A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes. J Contemp Brachytherapy 2019;10(2):155-161.
- \*Davis BJ, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012:6-19.
- \*Demanis DJ, et al. High-dose rate brachytherapy as monotherapy for prostate cancer. Brachytherapy Nov-Dec 2014;13(6):529-41.

**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER**

**Policy Number: 6.01.16**

**Page: 8 of 9**

- \*Dess RT, et al. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol 2019 Sep;37(9):599-610.
- \*Deville C, et al. Radiation therapy summary of the AUA/ASTRO guideline on clinically localized prostate cancer. Practical Rad Onc 2023;14:47-56.
- \*Fischer-Valuck BW, et al. A brief review of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy boost for high-risk prostate. Front Oncol 2019 Dec 10;9:1378.
- \*Goy BW, et al. Ten-year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1503 patients with intermediate-risk prostate cancer. Urology 2020 Feb;136:180-189.
- \*Henry A, et al. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiotherapy and Oncology 2022;167:244-251.
- \*Hoskin PJ, et al. Randomised trial of EBRT alone or with HDR for prostate cancer: mature 12-year results. Radiotherapy and Oncology 2021, 154:214-219.
- \*Kee DLC, Gal J, Falk AT, et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev 2018 Nov; 70:265-271.
- \*Kollmeier MA, et al. Favourable long-term outcomes with brachytherapy-based regimens in men  $\leq 60$  years with clinically localized prostate cancer. BJU Int 2013 Jun;111(8):1231-6.
- \*Lee DJ, et al. Comparison of patient-reported outcomes after external beam radiation therapy and combined external beam with low-dose-rate brachytherapy boost in men with localized prostate cancer. Int J Radiat Oncol Biol Phys 2018;102(1):116-126.
- \*Michalski JM, et al. Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG Oncology RTOG 0232 randomized clinical trial. J Clin Oncol 2023 Aug 20;41(24):4035-4044.
- \*Morris WJ et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017 June;98(2): 275-285.
- \*Morris WJ, et al. Using a surgical prostate-specific antigen threshold of 0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy 2018; 17(6): 837-844.
- \*National Comprehensive Cancer Network (NCCN). Prostate Cancer. Clinical practice guidelines in oncology. V.4.2024. [[http://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)] accessed 10/04/24.
- \*Pasalic D, et al. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer 2021 Jun; 127(11): 1912-1925.
- \*Potters L, et al. Permanent source brachytherapy for prostate cancer. American College of Radiology appropriateness criteria. Radiol 2000 Jun;215(Suppl):1383-400.
- \*Prada PJ, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results. Brachytherapy 2018 Nov-Dec;17(6):845-851.
- \*Rogers CL, et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012 Jan;187(1):109-16.
- \*Rosenthal SA, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2011;79(2):335-41.



**Medical Policy: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER**

**Policy Number: 6.01.16**

**Page: 9 of 9**

\*Siddiqui ZA, et al. Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2019 Aug 1;104(5):1038-1044.

\*Tang X, et al. The 100 most cited articles in prostate cancer brachytherapy: systematic review and bibliometric analysis. J Contemp Brachytherapy 2020 Jun; 12(3): 283–289.

\*Viani, GA, et al. HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis. Brachytherapy 2021, 20:307-314.

\*Key Article

**KEY WORDS**

High-dose rate brachytherapy, Low-dose rate brachytherapy, Permanent brachytherapy, Prostate brachytherapy, Temporary brachytherapy, image-guided radiation therapy.

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

Based on our review, Brachytherapy is not addressed in National or Regional Medicare coverage determinations or policies.

There is currently a Billing and Coding Article addressing Transrectal Ultrasound (A57427). Including prostate volume studies for brachytherapy treatment planning. Please refer to the following website for Medicare Members: [Article - Billing and Coding: Transrectal Ultrasound \(A57427\) \(cms.gov\)](#) accessed 11/21/24.